Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-33.3 %
ROCE
-- %
P/E Ratio
0.6
P/B Ratio
1.9
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
8,307,890
CFO
$-86.93 Mln
EBITDA
$-95.96 Mln
Net Profit
$-92.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bio Path Holdings Inc (BPTH)
| -84.1 | -- | -- | -91.3 | -86.7 | -71.7 | -64.4 |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Bio Path Holdings Inc (BPTH)
| -87.2 | -69.5 | -59.9 | 7.7 | -56.2 | 128.3 | -91.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bio Path Holdings Inc (BPTH)
|
0.2 | 1.7 | 0.0 | -9.6 | -- | -- | 0.6 | 1.9 |
| 49.3 | 7,861.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.4 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.4 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.5 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.1 | |
| 43.4 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 52.8 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 308.6 | 8,699.8 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.1 | 14.7 | |
| 25.7 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 125.8 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 5.0 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which... is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Read more
Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
Mr. Peter H. Nielsen MBA
Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
Mr. Peter H. Nielsen MBA
Headquarters
Bellaire, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bio Path Holdings Inc (BPTH) stood at $ 7 Mln as on 31-Mar-25
The share price of Bio Path Holdings Inc (BPTH) is $0.18 (NASDAQ) as of 23-Jun-2025 14:35 EDT. Bio Path Holdings Inc (BPTH) has given a return of -86.67% in the last 3 years.
Bio Path Holdings Inc (BPTH) has a market capitalisation of $ 2 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bio Path Holdings Inc (BPTH) is 1.90 times as on 20-Jun-2025, a 32% discount to its peers’ median range of 2.79 times.
The P/E ratio of Bio Path Holdings Inc (BPTH) is 0.58 times as on 20-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bio Path Holdings Inc (BPTH) and enter the required number of quantities and click on buy to purchase the shares of Bio Path Holdings Inc (BPTH).
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
The CEO & director of Mr. Peter H. Nielsen MBA. is Bio Path Holdings Inc (BPTH), and CFO & Sr. VP is Mr. Peter H. Nielsen MBA.
There is no promoter pledging in Bio Path Holdings Inc (BPTH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Bio Path Holdings Inc (BPTH) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bio Path Holdings Inc (BPTH) was $0 Mln.
$-0.03
(
